The drug market in India not only manufactures drugs to be used in the country but also for export to other countries of the world (Basak, 2018). There are different international policies and laws as well as country-specific laws that pharma companies need to follow for the export of drugs.
The health insurance policies help in controlling the mortality rate occurring from different diseases as well as allergic conditions. It has been constituted that at least 20% of the total Indian population suffer from different allergic conditions. On the other hand, 30% of the allergic population die due to lack of accessibility to medications and treatments.
However, the national health report of India in 2018 indicated 34% of the total population of India have health insurance coverage, 79% of them were covered by public insurance companies and government schemes.
The increasing prevalence of allergy in India has resulted in a big economic burden on the cost of treatment impacting allergic conditions treatment capability.
AYUSH treatment is gaining attention for treating spondylitis, arthritis, epilepsy, gallstone, and varied allergies. Its treatments are significantly higher in treating skin, muscular-skeletal related ailments, and persistent allergic conditions.
Atopic dermatitis presents the variation in prevalence gradients across geographically distinct areas. Hence, the investigation into economic burden of the disease is essential to understanding the impact in developing and developed regions.
For allergies, the risk factors can be divided into two broad categories, host and environmental factors. The interaction of different host and environmental factors is responsible for the phenotypic expression of allergies.
Currently, 300 million people suffer from asthma globally, of that one-tenth reside in India. Nearly 4,89,000 people die annually due to asthma. Majority of fatalities occur in low- and middle-income countries, such as the Middle East and Africa (Masoli et al., 2004).